---
schema_version: "secwatch.filing_event.v1"
accession: "0001830214-25-000009"
form_type: "8-K"
ticker: "DNA"
cik: "0001830214"
company_name: "Ginkgo Bioworks Holdings, Inc."
filed_at: "2025-09-04T23:59:59+00:00"
generated_at: "2026-05-17T08:21:10.007899+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Ginkgo Bioworks enters $100M at-the-market equity sales agreement with Allen & Company

## Summary
- Up to $100M in Class A common stock may be sold through Agent Allen & Company.
- Agent receives commission of up to 3% of gross proceeds from each sale.
- Registration statement on Form S-3 declared effective August 14, 2025; prospectus supplement dated Sept 4, 2025.
- Net proceeds to be used for general corporate purposes including operations, tech development, working capital.
- Company may terminate Sales Agreement with sufficient written notice; no assurance any shares will be issued.

## SEC filing metadata
- accession: 0001830214-25-000009
- form_type: 8-K
- ticker: DNA
- cik: 0001830214
- company_name: Ginkgo Bioworks Holdings, Inc.
- filed_at: 2025-09-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1830214/000183021425000009/0001830214-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1830214/000183021425000009/dna-20250904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001830214-25-000009
- JSON: https://secwatch.observer/filing/0001830214-25-000009.json
- Plain text: https://secwatch.observer/filing/0001830214-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.